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Abstract
For HIV-infected children, adherence to antiretroviral therapy (ART) is often assessed by 
caregiver-report but there are few data on their validity. We conducted prospective evaluations 
with 191 children ages 0 to 14 years and their caregivers over 6 months in western Kenya to 
identify questionnaire items that best predicted adherence to ART. Medication Event Monitoring 
Systems® (MEMS, MWV/AARDEX Ltd, Switzerland) electronic dose monitors were used as 
external criterion for adherence. We employed a novel variable selection tool using the LASSO 
technique with logistic regression to identify items best correlated with dichotomized MEMS 
adherence (≥90% or <90% doses taken). Nine of 48 adherence items were identified as the best 
predictors of adherence, including missed or late doses in the past 7 days, problems giving the 
child medicines, and caregiver-level factors like not being present at medication taking. These 
items could be included in adherence assessment tools for pediatric patients.
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INTRODUCTION
An estimated 3.4 million children under 15 years of age are infected with the Human 
Immunodeficiency Virus (HIV), with upwards of 90% living in sub-Saharan Africa [1]. 
Antiretroviral therapy (ART) significantly reduces HIV-related morbidity and mortality [2–
6] but good clinical outcomes require high and consistent adherence to ART [7–11]. 
Currently, no gold standard exists for how to accurately measure adherence to ART in 
routine clinical care, especially for HIV-infected children in resource-limited settings [12].
Adherence to ART is most commonly assessed through self-reported missed doses [13] and 
in the case of young HIV-infected children through caregiver report [14, 15]. Data are 
conflicting on the reliability of caregiver report to measure children’s adherence to ART [16, 
17]. Validated caregiver reported measures from the NIAID Pediatric Clinical Trials Group 
Studies have shown good correlation with virologic outcomes among children in the United 
States [18] but these measures have not been rigorously evaluated in resource-limited 
settings. Studies from sub-Saharan Africa that have investigated caregiver-reported 
adherence questions related to recall of missed doses in a certain period of time have 
indicated higher levels of adherence compared to more “objective” assessment methods like 
pill counts, pharmacy refill, and electronic drug monitoring (EDM) [19–21]. EDM is often 
the best measure in terms of correlation with virologic outcomes [22, 23], but is not 
recommended for routine adherence monitoring [24] and is too expensive for widespread 
use in resource-limited settings [25].
Routine assessment of adherence to ART is recommended by the International Association 
of Physicians in AIDS Care for all patients [24] and is essential to guide clinical decision-
making, especially in resource-limited settings where second- and third-line regimens are 
not typically available [26]. The objective of this study was to identify questionnaire items 
that could be asked to caregivers to accurately assess ART adherence among children in a 
large HIV treatment program in western Kenya. In this manuscript, we describe the first 
stage of the development of a reliable and valid pediatric ART adherence questionnaire.
METHODS
Study design
We conducted a prospective study utilizing a rigorous, iterative process to evaluate 
questionnaire items designed to measure pediatric adherence to ART and associated factors 
among 200 caregivers of HIV-infected children receiving care through the Academic Model 
Providing Access to Healthcare (AMPATH) in Eldoret, Kenya. Item selection for the 
adherence questionnaire was informed by literature review, expert panel consultation, and 
formal qualitative work in this setting in western Kenya [27, 28]. Qualitative methods 
included individual and group cognitive assessments with caregivers of HIV-infected 
children about adherence items using verbal probing and guided “thinking aloud” to 
evaluate relevance, comprehension, recall, sensitivity, and acceptability of the questions. 
Key findings from qualitative analysis included differences in responses by recall period, 
benefits of including normalizing statements before asking for sensitive information, 
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challenges processing categorical frequency scales, and optimized response items and 
question wording [28].
Together, these efforts yielded 48 items for assessing adherence to ART among Kenyan 
children that were compiled into a questionnaire. Questionnaire items included late doses 
and missed doses (in the past 3, 7 and 30 days), doses taken by visual analog scale (VAS), 
adherence barriers, social barriers like HIV/AIDS stigma, and household characteristics 
(questionnaire included in Electronic Supplementary Materials). The items were translated 
into Kiswahili, one of the regional and national languages, with good face validity and 
understandability [28]. We only present data from questionnaire items administered to the 
caregivers; child participants who reported responsibility for their medication taking were 
asked questions about their adherence but these will be reported elsewhere.
Children were followed for exactly 6 months and each caregiver had the adherence 
questionnaire administered to them a total of 7 times at approximately 1 month intervals. 
Trained study personnel verbally administered the adherence questionnaire in Kiswahili or 
English (dependent on caregiver’s preference) to caregivers at study visits. Adherence items 
were evaluated by comparison with Medication Event Monitoring Systems® (MEMS, 
MWV/AARDEX Ltd, Switzerland) that use a microcircuit to record the time and date 
whenever the medication bottle is opened. At study initiation, all study participants received 
and were trained in using the MEMS bottles and data from MEMS were downloaded at 
monthly study visits. MEMS were chosen as the reference measure as they show better 
correlation with virological outcomes compared to other adherence measures like pharmacy 
refill or pill counts and have been used in similar studies evaluating adherence measures 
[23]. MEMS also allow for investigating patterns of adherence, which may be particularly 
important for the design of adherence interventions. This study was approved by the 
Institutional Review Board at Indiana University School of Medicine in Indianapolis, 
Indiana, USA and by the Institutional Research and Ethics Committee at Moi University 
School of Medicine in Eldoret, Kenya.
Study participants
The study population was dyads of caregivers and their HIV-infected children ages 0 to 14 
years. The children were on either a nevirapine- (NVP) or efavirenz- (EFV) based first-line 
ART regimen and enrolled in care at AMPATH – a large HIV treatment program in western 
Kenya [29, 30]. Caregiver-child dyads were followed for 6 months of prospective adherence 
assessments. HIV infection was defined as having one positive HIV DNA PCR test or one 
positive HIV ELISA antibody test. Children above 14 years of age were not enrolled as they 
are usually treated in the AMPATH adult care setting. As the primary objective of this study 
was to evaluate caregiver-reported adherence, we focused on younger children as older 
children take more responsibility for their own medication taking and likely have very 
different adherence challenges as they enter early- to mid-adolescence. Caregivers were 
defined as an individual who accompanied the child to clinical and study visits and reported 
having responsibility or knowledge of the child’s medication taking. Caregivers could be 
primary or secondary, biological or non-biological caregivers. Clinic nurses and clinicians, 
as well as study staff, screened a convenience sample of clinic attendees for potential study 
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participants who met inclusion criteria and referred them to learn about the study. 
Participants could also self-refer. Out of a total of 210 caregivers and children approached to 
participate in the study, 10 declined to participate. Informed consent was obtained for all 
caregivers and assent for any child 10 years and above following standard locally-approved 
research protocols. A small incentive was provided for participation to help cover 
transportation costs and time.
Data analysis
We used a novel variable selection method called the Least Absolute Shrinkage and 
Selection Operator (LASSO) to select adherence questionnaire items that best correlated 
with dichotomized MEMS adherence [31, 32]. Unlike traditional multivariate regression 
models that suffer from numerical instability when examining a large number of 
independent variables, the LASSO-based variable selection method helps to shrink the less 
important regression coefficients to zero, leaving only the items that strongly correlate with 
the adherence outcome in the model. In this study, we used the variable selection method to 
identify items that were most predictive of MEMS adherence. MEMS adherence was 
dichotomized as ≥90% or <90% of all doses taken at each monthly study visit. 
Dichotomization at the level of 90% was chosen to be consistent with other studies 
comparing adherence measures to MEMS [33, 34]. Moreover, studies show that adherence 
below 90% significantly increases the risk for virologic rebound and drug resistance [35–
37].
LASSO models were run for each study visit except baseline (total of 6 variable selection 
models). We used visit-level variable selection logistic regression models as the primary 
analysis to detect factors that correlated with concurrently measured ART adherence 
because adherence exhibits temporal variations [38]. Items that showed consistency in their 
correlation to MEMS adherence across LASSO models (defined as significant at 2 or more 
study visits) were used to calculate a summary risk score for non-adherence. The risk score 
was intended to test whether a composite measure of multiple items correlating well with 
MEMS adherence could be used together to predict patients at risk of non-adherence. The 
risk score was calculated as the sum of individual items weighted by the corresponding 
regression coefficients. We then assessed the accuracy of the summary score of the selected 
items in predicting the dichotomized MEMS adherence outcome at each visit. We examined 
the receiver operating characteristic (ROC) curves of the risk score and reported the area 
under the ROC curve (C-statistic) for each visit. To increase the robustness of analysis, 
sensitivity analyses were conducted at different MEMS adherence dichotomization points 
(80%, 85%, 95%, and 99%) and no significant differences were found in the items selected 
by LASSO or by the items’ predictive value. Thus, only the results from dichotomizing 
adherence at the 90% level are presented.
In addition to visit-level analyses, we conducted repeated measures logistic regression 
analysis to assess the association between LASSO-selected independent variables (i.e., 
variables significant in LASSO analysis at 2 or more study visits) and dichotomized MES 
adherence (≥90% or <90%) over time. Sensitivity analyses using different adherence 
dichotomization points were also performed, as described above. We used the generalized 
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estimating equation (GEE) technique to accommodate within-subject correlation from 
repeated measures. In the multivariate model, patients’ baseline demographic variables were 
adjusted as covariates (age, gender, and duration on ART) and we ran correlation matrices 
on adherence items selected by the LASSO method to ensure proper model fit. Adjusted 
odds ratios (OR) and corresponding 95% confidence intervals (CI) are reported. Statistical 
analyses were performed using R 3.0.1 (Vienna, Austria) and SAS v9.3 (SAS Institute, 
Cary, NC, USA).
RESULTS
Study Participant Characteristics
One hundred ninety-one caregiver-child dyads completed the study (9 out of the original 200 
participants did not complete the study because they withdrew from the study or the child 
died). Mean age of HIV-infected children at enrollment was 8.2 years and 55% were female 
(Table I). Children had a mean weight-for-age Z (WAZ) score of −1.7, which is low but 
within the “normal” range (WHO classifies a WAZ score between −2 and 2 as within the 
“normal” range, <−2 as mild malnutrition, and <−3 as severe malnutrition) [39]. Most 
children were on twice daily NVP-based regimens (77%) versus once-daily EFV-based 
regimens and mean duration on ART was 2.3 years. Only 23% of caregivers reported that 
their child knew their HIV status. Most caregiver participants were the child’s biological 
mother (63%) but a number of biological fathers (11%) and grandparents (7%) participated 
as well. When caregivers were asked to list all persons who had partial or full responsibility 
for the child’s medication taking, biological mothers were most commonly responsible 
(84%), followed by the child’s sibling (42%), father (36%), or other relative in the home 
(36%). Thirty-one percent of caregivers reported that the child was at least partially 
responsible for his or her own medication taking. Poverty was high in this cohort; 70% of 
caregivers reported there was not enough food for their family in the past 30 days and 83% 
reported having financial difficulty with transportation to clinic.
Median adherence was 93% by MEMS over the 6-month period but improved over the 
course of the study (Figure I). While 51% of children had ≥90% MEMS adherence at month 
1, 64% achieved ≥90% MEMS at month 2, and between 67–68% at following months. Only 
29% maintained ≥90% MEMS adherence over the course of 6 months. MEMS treatment 
interruptions were common in this cohort; 49.5% of children had at least one treatment 
interruption of ≥48 hours in 6 months with a median of 3 treatment interruptions per child 
during the study period (range 0 to 17, IQR 0–6). There were few missing adherence data; 
over 94% of children had complete MEMS adherence data across all visits, while 4% of 
children had missing data at only 1 visit and 2% of children had missing data at 2 visits. No 
children had missing adherence data at 3 or more visits.
Adherence item selection
Eighteen out of the 48 questionnaire items had non-zero effects in by-visit variable selection 
regression analyses and thus were correlated with MEMS adherence (Table II). Nine of 
these items had non-zero effects at 2 or more visits and met the more rigorous criteria for 
inclusion in the calculation of the risk score and logistic regression analysis. C-statistics 
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from ROC curve analysis across visits ranged from 0.61 to 0.78. Significant domains of the 
selected items that were associated with MEMS non-adherence included reported missed 
doses in the past 7 days and 30 days, doses given more than 1 hour late in the past 7 days, 
enrollment in AMPATH’s nutrition program, difficulty giving the child medicines on time, 
the child refusing to take the medicines, and a higher number of reported caregiver-level 
barriers. Caregiver-level barriers were significant at 2 visits (visit 3 and visit 5) and included 
the caregiver not being around to give the medicines, not wanting to give the medicines 
around others, and forgetting to give the medicines, among others. Child-level barriers were 
significant at 3 visits, but showed inconsistent relationships with adherence; at visit 2 and 
visit 6 reporting child-level barriers was associated with non-adherence but at visit 5 
reporting child-level barriers was associated with higher adherence.
After adjusting for demographic characteristics and within-subject correlation, 4 out of the 9 
selected items were statistically significant in a repeated measure analysis using GEE (Table 
III). Items associated with <90% MEMS adherence were problems getting the child to take 
the medicines (OR 0.43, 95%CI 0.22–0.83), the caregiver reporting 1 or more caregiver-
level barriers (OR 2.20, 95%CI 1.06–4.56), missing at least one dose in the past 7 days (OR 
1.79, 95%CI 1.07–3.01), and giving a dose more than one hour late in the past 7 days (OR 
1.26, 95%CI 1.08–1.47). While it was not significant in the LASSO selection method, a 
child’s duration on ART was associated with MEMS in GEE analysis; longer time on ART 
was associated with MEMS non-adherence (OR 1.09, 95%CI 1.00–1.19).
DISCUSSION
The results of this study suggest that certain caregiver-report questionnaire items perform 
better than others in reflecting a child’s adherence to ART. While adherence questionnaire 
items varied widely in their association with MEMS, we identified several items with 
stronger correlations that may be used as part of low-cost, routine adherence assessment 
tools for pediatric HIV patients on ART. To our knowledge, this is the first study evaluating 
caregiver-reported adherence questionnaire items against electronic dose monitoring using 
this type of variable selection method. Rigorously validated questionnaire items have not 
previously been available for pediatric adherence evaluation in resource-limited settings, 
hampering efforts to monitor adherence. Future studies may benefit from this rigorous 
methodological approach, namely the use of the LASSO section tool, to evaluate the 
performance of a large and diverse set of questionnaire items related to adherence to ART or 
in other areas.
A major strength of our study was testing a broad range of adherence items from different 
domains. Furthermore, the domains informing item inclusion for testing were identified 
through formative qualitative work in this setting with further cross-cultural adaptation using 
cognitive interviewing and other qualitative techniques [27, 28]. While commonly used 
questions about missed doses performed relatively well (at least 30-day and 7-day missed 
doses), we found that questions around adherence barriers, specifically problems with dose 
timing, caregiver forgetting, and social issues like HIV/AIDS stigma (adherence barriers 
included in our questionnaire are given in Table IV), were also predictive of non-adherence 
among this population. This is consistent with a number of studies that showed more 
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nuanced caregiver-reported difficulties in giving their child medicines or understanding of 
medical regimens were associated with viral load [16, 40, 41]. Our findings provide further 
evidence for the relationship between these broader domains of a family’s psychosocial 
situation and adherence-related behaviors. These results have practical implications for 
practitioners conducting adherence assessments and counseling with patients and should 
encourage the further investigation of how psychosocial factors impact adherence and how 
these barriers can be identified.
For settings like western Kenya, developing low-cost adherence measurement tools is 
critical. Using the caregiver-reported items that were predictive of MEMS adherence in this 
study (i.e., 9 items selected by LASSO), we will now undertake further testing and 
validation of these items in a short-version adherence questionnaire delivered by clinicians 
rather than research teams. Reliability and validity testing of the short-version adherence 
questionnaire will be conducted in 3 countries (2 in sub-Saharan Africa and 1 in Asia) using 
MEMS monitoring again as the reference standard. If successful, it is our hope that this 9-
item adherence questionnaire can be used as a global adherence screening tool to identify 
children who may need further adherence evaluation or adherence counseling and that the 
tool is brief but reliable enough to use for routine adherence monitoring for all pediatric 
patients on ART. In busy clinical settings like AMPATH, clinicians do not have time to 
conduct intensive adherence counseling with children and caregivers; however, a short 
adherence screening tool using validated items might allow clinic staff to identify children 
who are at higher risk for non-adherence and can then be targeted for further adherence 
assessments or interventions. Finally, there is a dearth of data on adherence interventions 
and counseling for children on ART in resource-limited settings, which is certainly 
hampered by the lack of reliable adherence measures [42]. A validated adherence 
questionnaire will allow cheaper and longer follow-up of children to evaluate these 
interventions and ultimately to improve the care and survival of HIV-infected children.
This study has a number of potential limitations for consideration. First, this study employed 
convenience sampling that introduces potential selection bias and in this case might have led 
to children who had excellent adherence or very low adherence being more likely to enroll. 
Second, our analysis relied on the validity of MEMS to accurately measure adherence. 
Electronic dose monitoring using MEMS has shown high correlation with viral load levels 
and has been commonly utilized to both describe adherence and compare adherence 
measurement techniques in resource-limited settings [17, 19, 25, 43–45]; however, there are 
a number of potential weaknesses in using MEMS that have not been adequately explored in 
this setting [44, 46]. We attempted to overcome many of the challenges of daily MEMS use 
by training and educating the families about how and why to use the MEMS bottles and 
asking them about any problems or difficulties with the MEMS at each study encounter. 
Third, participants were aware that their medications were in the MEMS bottles, which may 
have impacted their medication-taking behavior. We did see a significant increase in 
adherence to ART by MEMS, particularly from month 1 to month 2, suggesting that some 
part of the study procedures (e.g., use of MEMS, adherence questionnaire, interaction with 
study personnel, etc.) may have had an intervention effect. Any such effect on adherence 
behaviors should not have impacted our results as the goal was to identify which 
questionnaire items accurately predicted MEMS adherence levels at each visit, whether it 
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was increasing or decreasing. Fourth, we used visit-level models to evaluate the 
performance of adherence items. This approach gave us the ability to detect month-to-month 
changes in associations between independent variables and adherence levels; however, this 
also weakened our ability to measure overall or composite associations. We addressed this 
potential weakness by conducting two separate analyses using composite variables across 
the 6 visits that showed good consistency with the visit-level model (data not shown). 
Although the variable selection method can effectively identify important independent 
variables, the estimated non-zero coefficients for the selected items do not have estimation 
variability measures (i.e., confidence intervals). To overcome this, GEE analysis based on 
LASSO-selected items was performed to provide the variability estimates. Finally, we used 
cross-cultural adaptation and grounded formative work to inform the specific wording of 
questionnaire items and the content of the domains were adapted to the particular cultural 
context in western Kenya. The suitability of these questions in other settings is unclear 
though we anticipate that the general domains of inquiry could still be broadly applicable 
across global pediatric HIV care sites. Further work in reliability and validity testing of the 
adherence questionnaire items are being undertaken.
CONCLUSIONS
We found that caregiver reported adherence among HIV-infected children varied 
significantly by different questionnaire items in their association with MEMS. Certain 
adherence questionnaire items related to missed and late doses and those related to child- 
and caregiver-level adherence barriers performed better and may be used as part of an 
adherence screening questionnaire. More extensive validity and reliability testing of these 
candidate items is ongoing to better inform adherence assessment tools for pediatric 
adherence to ART in resource-limited settings.
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Figure I. 
Adherence to ART by Medication Event Monitoring Systems
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Table I
Study participants’ characteristics
Child characteristics (N=191) Mean (Standard Deviation) or Frequency (%)
Age (years) 8.2 (3.3)
Female 105 (55%)
Weight-for-age Z (WAZ) Score −1.7 (1.3)
ART duration (years) 2.3 (1.9)
ART Regimen
 NVP 148 (77%)
 EFV 43 (22%)
 NVP/EFV (both) 2 (1%)
CD4% 26 (11)
WHO Stage (at baseline)
 1 34 (18%)
 2 32 (17%)
 3 104 (54%)
 4 18 (9%)
 Not answered 3 (2%)
Child disclosure status
 Child disclosed (knows HIV status) 44 (23%)
Caregiver characteristics (N=191) Mean (Standard Deviation) or Frequency (%)
Caregiver relationship to child
 Mother 120 (63%)
 Father 21 (11%)
 Grandparent 13 (7%)
 Non-related caregiver 7 (4%)
 Sibling 3 (1%)
 Other 27 (14%)
Caregiver employed outside the household 99 (52%)
Enrolled in AMPATH nutrition program 33 (17%)
Food insecurity (reported “not enough food for family in past 30 days”) 134 (70%)
Difficulty with transportation to clinic 159 (83%)
Individuals reported as ever giving child medicines
 Mother 160 (84%)
 Father 68 (36%)
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Child characteristics (N=191) Mean (Standard Deviation) or Frequency (%)
 Sibling 80 (42%)
 Relative (inside home) 68 (36%)
 Child takes own medicine 60 (31%)
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Table III
GEE model results for LASSO-selected items
Adherence Variable Item Number Odds Ratio 95% Confidence Interval
Ever have problems keeping time with the medicines 12 0.96 0.65–1.44
Currently enrolled in AMPATH nutrition program 17 0.50 0.22–1.10
Ever have problems getting child to take medicinesa 18 0.43 0.22–0.83
How many doses of medicine has child missed in last month 23 1.15 0.87–1.52
Child-level factors make it difficult to give medicines 24 1.25 0.57–2.77
Caregiver-level factors make it difficult to give medicinesa 25 2.20 1.06–4.56
Number of days missed at least one dose in past weeka 34b 1.79 1.07–3.01
Number of days dose given more than one hour late in past weeka 34c 1.26 1.08–1.47
Number of extra doses in past week 34f 1.04 0.81–1.33
Demographic variables included for multivariate analyses
Gender n/a 1.16 0.84–1.60
Age (yrs) n/a 0.99 0.85–1.15
Duration on ART (yrs) n/a 1.09 1.00–1.19
aVariable significant in multivariate regression p<.05
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Table IV
Caregiver- and child-level barriers
Caregiver-level barriers
25. Sometimes, a child does not take their medicines every day or at the same time every day because of difficulties for the caregiver. I am 
going to read a list of issues that may be problems for you as a caregiver in having the child take the medicines. Stop me when you hear a 
problem mentioned that applies to you.
□ I had difficulty with reading instructions □ I thought other matters were more urgent
□ I did not understand the medication instructions □ I was away from home (work, field, etc.)
□ I thought treatment was completed □ I was discouraged or losing hope
□ I was not always around with the child □ There were frequent changes in caregivers
□ I was taking alcohol or other drugs □ Caregiver being too busy and forgetting
□ I did not want others to see □ I was not aware of child’s status
□ I had trouble with timing or giving the doses on time □ I wanted to try another treatment or prayers
□ I did not think the drugs were helping □ Other (specify)
□ I thought child needed a break from the medicines □ None of the above
□ I was afraid of side effects on child
Child-level barriers
24. Some families tell us that their child worries them or makes it difficult to give them the medicines. Has your child not taken medicines for 
any of these reasons:
□ He/she does not know why taking the medicines or keeps asking 
questions about the medicines
□ Can’t take without food
□ He/she did not understand the medication instructions □ He/she forgot to take medicine
□ He/she was playing or at school or work □ He/she refused to take medicine
□ He/she felt ill or was vomiting □ He/she felt better
□ He/she does not want others to see the medicines □ He/she believes medicine does not help
□ He/she had harm or side effects caused by the drugs □ Has problems with 1 formulation (tablets, liquids)
□ Finds medicines too bitter □ Other (specify)
□ He/she is tired of taking the medicines □ None of the above
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